Despite the labeling of IL2 that has been attempted over the past decades, with both single-photon-emitting and positron-emitting isotopes for imaging activated T-lymphocytes in many cancers and autoimmune disorders, labeling procedures have often been costly and time-consuming, thus limiting clinical applications. This evidence concerns the gene IL2 and cancer.